📊 AYTU Key Takeaways
Is Aytu Biopharma, Inc. (AYTU) a Good Investment?
AYTU BioPharma faces fundamental operational distress with a net loss of $14.2M on minimal revenue growth (+1.8% YoY), negative operating cash flow, and deteriorating profitability despite a healthy 63.7% gross margin. The massive gap between gross and operating margins indicates uncontrolled SG&A/R&D spending with unclear returns, compounded by tight liquidity and limited cash runway given current burn rates.
AYTU Biopharma shows solid gross profitability and positive free cash flow, but those strengths are outweighed by persistent operating and net losses, weak interest coverage, and a thin equity base. Revenue growth is minimal, so the current cash generation needs to prove durable rather than temporary, especially given the company’s negative margins and constrained balance sheet flexibility.
Aytu Biopharma, Inc. Key Strengths (AYTU)
- Decent gross margin of 63.7% indicates viable product economics
- Positive cash position of $26.7M provides near-term liquidity buffer
- Moderate leverage with Debt/Equity ratio of 0.27x limits financial distress risk
- Gross margin of 64.7% indicates the core product portfolio has reasonable pricing power and favorable unit economics before overhead
- Operating cash flow of $3.06M and free cash flow of $3.04M provide near-term liquidity support despite accounting losses
- Cash balance of $30.02M and quick ratio of 1.03x suggest the company can currently meet near-term obligations without severe immediate stress
AYTU Stock Risks: Aytu Biopharma, Inc. Investment Risks
- Massive unprofitability: operating loss of $7.5M (18.2% margin) on $41.5M revenue
- Negative operating cash flow of $1.1M indicates core business is not self-sustaining
- Anemic revenue growth of 1.8% YoY suggests weak market position or failed commercialization
- Tight working capital with current ratio of 1.12x; cash runway vulnerable to continued burn
- Severe shareholder value destruction with ROE of -40.5% and ROA of -12.7%
- No insider activity in 90 days suggests lack of confidence from management
- Operating margin of -12.0% and net margin of -29.7% show the business is still not sustainably profitable
- ROE of -60.7% and stockholders equity of only $14.20M indicate a weak capital base relative to losses and liabilities
- Interest coverage of -1.7x and current ratio of 1.16x leave limited room if cash flow weakens or financing conditions tighten
Key Metrics to Watch
- Operating cash flow trajectory - critical inflection point for viability
- Revenue growth acceleration - need sustained growth above 1.8% to justify R&D spending
- Operating margin improvement - path to breakeven is essential
- Cash burn rate and months of runway remaining
- Product pipeline milestones and commercial success metrics
- Sustained improvement in operating income and operating margin
- Operating cash flow quality versus net losses, including working capital dependence
Aytu Biopharma, Inc. (AYTU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Aytu Biopharma, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AYTU Profit Margin, ROE & Profitability Analysis
AYTU vs Healthcare Sector: How Aytu Biopharma, Inc. Compares
How Aytu Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aytu Biopharma, Inc. Stock Overvalued? AYTU Valuation Analysis 2026
Based on fundamental analysis, Aytu Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aytu Biopharma, Inc. Balance Sheet: AYTU Debt, Cash & Liquidity
AYTU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aytu Biopharma, Inc.'s revenue has shown modest growth of 1% over the 5-year period. The most recent EPS of $-74.01 indicates the company is currently unprofitable.
AYTU Revenue Growth, EPS Growth & YoY Performance
AYTU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $12.4M | $788.0K | $0.21 |
| Q2 2026 | $15.2M | $788.0K | $-0.26 |
| Q1 2026 | $13.9M | $1.5M | $-0.08 |
| Q3 2025 | $14.0M | -$220.0K | $0.21 |
| Q2 2025 | $16.2M | -$220.0K | $-0.04 |
| Q1 2025 | $16.6M | $1.5M | $-0.15 |
| Q3 2024 | $18.0M | -$220.0K | N/A |
| Q2 2024 | $22.9M | -$220.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aytu Biopharma, Inc. Dividends, Buybacks & Capital Allocation
AYTU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aytu Biopharma, Inc. (CIK: 0001385818)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AYTU
What is the AI rating for AYTU?
Aytu Biopharma, Inc. (AYTU) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AYTU's key strengths?
Claude: Decent gross margin of 63.7% indicates viable product economics. Positive cash position of $26.7M provides near-term liquidity buffer. ChatGPT: Gross margin of 64.7% indicates the core product portfolio has reasonable pricing power and favorable unit economics before overhead. Operating cash flow of $3.06M and free cash flow of $3.04M provide near-term liquidity support despite accounting losses.
What are the risks of investing in AYTU?
Claude: Massive unprofitability: operating loss of $7.5M (18.2% margin) on $41.5M revenue. Negative operating cash flow of $1.1M indicates core business is not self-sustaining. ChatGPT: Operating margin of -12.0% and net margin of -29.7% show the business is still not sustainably profitable. ROE of -60.7% and stockholders equity of only $14.20M indicate a weak capital base relative to losses and liabilities.
What is AYTU's revenue and growth?
Aytu Biopharma, Inc. reported revenue of $41.5M.
Does AYTU pay dividends?
Aytu Biopharma, Inc. does not currently pay dividends.
Where can I find AYTU SEC filings?
Official SEC filings for Aytu Biopharma, Inc. (CIK: 0001385818) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AYTU's EPS?
Aytu Biopharma, Inc. has a diluted EPS of $-1.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AYTU's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aytu Biopharma, Inc. has a C grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AYTU stock overvalued or undervalued?
Valuation metrics for AYTU: ROE of -40.5% (sector avg: 15%), net margin of -34.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AYTU's AI grade for 2026?
Our dual AI analysis gives Aytu Biopharma, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AYTU's free cash flow?
Aytu Biopharma, Inc.'s operating cash flow is $-1.1M, with capital expenditures of $17.0K. FCF margin is -2.8%.
How does AYTU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -34.3% (avg: 12%), ROE -40.5% (avg: 15%), current ratio 1.12 (avg: 2).